Impact of concomitant cardiovascular medications on overall survival in patients with liver cirrhosis

References

• Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371(9615):838–851. doi: 10.1016/S0140-6736(08)60383-9.
   PubMed Web of Science ®Google Scholar
• Ginès P, Krag A, Abraldes JG, et al. Liver cirrhosis. Lancet. 2021;398(10308):1359–1376. doi: 10.1016/S0140-6736(21)01374-X.
   PubMed Web of Science ®Google Scholar
• Ginés P, Quintero E, Arroyo V, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology. 1987;7(1):122–128. doi: 10.1002/hep.1840070124.
   PubMed Web of Science ®Google Scholar
• D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006; 44(1):217–231. doi: 10.1016/j.jhep.2005.10.013.
   PubMed Web of Science ®Google Scholar
• Llach J, Ginès P, Arroyo V, et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology. 1988;94(2):482–487. doi: 10.1016/0016-5085(88)90441-6.
   PubMed Web of Science ®Google Scholar
• Sepanlou SG, Safiri S, Bisignano C, et al. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol. 2020;5(3):245–266. doi: 10.1016/S2468-1253(19)30349-8.
   PubMed Web of Science ®Google Scholar
• Jepsen P, Vilstrup H, Andersen PK, et al. Comorbidity and survival of Danish cirrhosis patients: a nationwide population-based cohort study. Hepatology 2008;48(1):214–220. Juldoi: 10.1002/hep.22341.
   PubMed Web of Science ®Google Scholar
• Jepsen P, Vilstrup H, Lash TL. Development and validation of a comorbidity scoring system for patients with cirrhosis. Gastroenterology 2014;146(1):147–156. doi: 10.1053/j.gastro.2013.09.019.
   PubMed Web of Science ®Google Scholar
• Chang WH, Mueller SH, Chung SC, et al. Increased burden of cardiovascular disease in people with liver disease: unequal geographical variations, risk factors and excess years of life lost. J Transl Med. 2022;20(1):2. doi: 10.1186/s12967-021-03210-9.
   PubMed Web of Science ®Google Scholar
• Stahl EP, Dhindsa DS, Lee SK, et al. Nonalcoholic fatty liver disease and the heart: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(8):948–963. doi: 10.1016/j.jacc.2018.11.050.
   PubMed Web of Science ®Google Scholar
• Ismaiel A, Dumitraşcu DL. Cardiovascular risk in fatty liver disease: the liver-heart axis—literature review. Front Med. 2019;6:202. doi: 10.3389/fmed.2019.00202.
   PubMed Web of Science ®Google Scholar
• Lee KK, Stelzle D, Bing R, et al. Global burden of atherosclerotic cardiovascular disease in people with hepatitis C virus infection: a systematic review, meta-analysis, and modelling study. Lancet Gastroenterol Hepatol. 2019;4(10):794–804. doi: 10.1016/S2468-1253(19)30227-4.
   PubMed Web of Science ®Google Scholar
• Mellinger JL, Volk ML. Multidisciplinary management of patients with cirrhosis: a need for care coordination. Clin Gastroenterol Hepatol. 2013;11(3):217–223. doi: 10.1016/j.cgh.2012.10.040.
   PubMed Web of Science ®Google Scholar
• Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64(12):1147–1161. doi: 10.1007/s00228-008-0553-z.
   PubMed Web of Science ®Google Scholar
• Palatini P, De Martin S. Pharmacokinetic drug interactions in liver disease: an update. World J Gastroenterol. 2016;22(3):1260–1278. doi: 10.3748/wjg.v22.i3.1260.
   PubMed Web of Science ®Google Scholar
• Homepage of OHDSI [Internet]. [cited 2022 Oct 20]. Available from: https://www.ohdsi.org/.
   Google Scholar
• Hripcsak G, Duke JD, Shah NH, et al. Observational health data sciences and informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574–578.
   PubMedGoogle Scholar
• Vassallo P, Trohman RG. Prescribing amiodarone. JAMA. 2007;298(11):1312–1322. doi: 10.1001/jama.298.11.1312.
   PubMed Web of Science ®Google Scholar
• Hamilton D, Nandkeolyar S, Lan H, et al. Amiodarone: a comprehensive guide for clinicians. Am J Cardiovasc Drugs. 2020;20(6):549–558. doi: 10.1007/s40256-020-00401-5.
   PubMed Web of Science ®Google Scholar
• Ziff OJ, Kotecha D. Digoxin: the good and the bad. Trends Cardiovasc Med. 2016;26(7):585–595. doi: 10.1016/j.tcm.2016.03.011.
   PubMed Web of Science ®Google Scholar
• Chokesuwattanaskul R, Thongprayoon C, Bathini T, et al. Epidemiology of atrial fibrillation in patients with cirrhosis and clinical significance: a meta-analysis. Eur J Gastroenterol Hepatol. 2019;31(4):514–519. doi: 10.1097/MEG.0000000000001315.
   PubMed Web of Science ®Google Scholar
• Darrat YH, Smer A, Elayi CS, et al. Mortality and morbidity in patients with atrial fibrillation and liver cirrhosis. World J Cardiol. 2020;12(7):342–350. doi: 10.4330/wjgs.v12.i7.342.
   PubMed Web of Science ®Google Scholar
• Yoshiji H, Nagoshi S, Akahane T, et al. Evidence-based clinical practice guidelines for liver cirrhosis 2020. J Gastroenterol. 2021;56(7):593–619. doi: 10.1007/s00535-021-01788-x.
   PubMed Web of Science ®Google Scholar
• Angeli P, Bernardi M, Villanueva C, et al. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406–460. doi: 10.1016/j.jhep.2018.03.024.
   PubMed Web of Science ®Google Scholar
• Kim G, Kim J, Lim YL, et al. Renin–angiotensin system inhibitors and fibrosis in chronic liver disease: a systematic review. Hepatol Int. 2016;10(5):819–828. doi: 10.1007/s12072-016-9705-x.
   PubMed Web of Science ®Google Scholar
• Tox U, Steffen H. Impact of inhibitors of the renin-angiotensin-aldosterone system on liver fibrosis and portal hypertension. Curr Med Chem. 2006;13(30):3649–3661. doi: 10.2174/092986706779026138.
   PubMed Web of Science ®Google Scholar
• Rodrigues SG, Mendoza YP, Bosch J. Beta-blockers in cirrhosis: evidence-based indications and limitations. JHEP Rep. 2020;2(1):100063. doi: 10.1016/j.jhepr.2019.12.001.
   PubMedGoogle Scholar
• Lebrec D, Poynard T, Hillon P, et al. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis. N Engl J Med. 1981;305(23):1371–1374. doi: 10.1056/NEJM198112033052302.
   PubMed Web of Science ®Google Scholar
• Pascal J-P, Cales P. Propranolol in the prevention of first upper gastrointestinal tract hemorrhage in patients with cirrhosis of the liver and esophageal varices. N Engl J Med. 1987;317(14):856–861. doi: 10.1056/NEJM198710013171403.
   PubMed Web of Science ®Google Scholar
• Pérez-Ayuso RM, Piqué JM, Bosch J, et al. Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis. Lancet. 1991;337(8755):1431–1434. doi: 10.1016/0140-6736(91)93125-s.
   PubMed Web of Science ®Google Scholar
• Senzolo M, Cholongitas E, Burra P, et al. β-Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. Liver Int. 2009;29(8):1189–1193. doi: 10.1111/j.1478-3231.2009.02038.x.
   PubMed Web of Science ®Google Scholar
• Villanueva C, Albillos A, Genescà J, et al. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2019;393(10181):1597–1608. doi: 10.1016/S0140-6736(18)31875-0.
   PubMed Web of Science ®Google Scholar
• Ge PS, Runyon BA. Treatment of patients with cirrhosis. N Engl J Med. 2016;375(8):767–777. doi: 10.1056/NEJMra1504367.
   PubMed Web of Science ®Google Scholar
• Itzel T, Falconer T, Roig A, et al. Efficacy of co-medications in patients with alcoholic liver disease. Dig Dis. 2023:1–9. doi: 10.1159/000529914. Online ahead of print.
   PubMed Web of Science ®Google Scholar
• Zermatten MG, Fraga M, Moradpour D, et al. Hemostatic alterations in patients with cirrhosis: from primary hemostasis to fibrinolysis. Hepatology. 2020;71(6):2135–2148. doi: 10.1002/hep.31201.
   PubMed Web of Science ®Google Scholar
• Lisman T, Hernandez-Gea V, Magnusson M, et al. The concept of rebalanced hemostasis in patients with liver disease: communication from the ISTH SSC working group on hemostatic management of patients with liver disease. J Thromb Haemost. 2021;19(4):1116–1122. doi: 10.1111/jth.15239.
   PubMed Web of Science ®Google Scholar
• Czajka P, Przybyłkowski A, Nowak A, et al. Antiplatelet drugs and liver fibrosis. Platelets. 2022;33(2):219–228. doi: 10.1080/09537104.2021.1883574.
   PubMed Web of Science ®Google Scholar
• Li CJ, Yang ZH, Shi XL, et al. Effects of aspirin and enoxaparin in a rat model of liver fibrosis. World J Gastroenterol. 2017;23(35):6412–6419. doi: 10.3748/wjg.v23.i35.6412.
   PubMed Web of Science ®Google Scholar
• Mahmoud NI, Messiha BAS, Salehc IG, et al. Interruption of platelets and thrombin function as a new approach against liver fibrosis induced experimentally in rats. Life Sci. 2019;231(January):116522. doi: 10.1016/j.lfs.2019.05.078.
   PubMed Web of Science ®Google Scholar
• Schwarzkopf K, Bojunga J, Rüschenbaum S, et al. Use of antiplatelet agents is inversely associated with liver fibrosis in patients WITH cardiovascular disease. Hepatol Commun. 2018;2(12):1601–1609. doi: 10.1002/hep4.1254.
   PubMed Web of Science ®Google Scholar
• Thongtan T, Deb A, Vutthikraivit W, et al. Antiplatelet therapy associated with lower prevalence of advanced liver fibrosis in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Indian J Gastroenterol. 2022;41(2):119–126. doi: 10.1007/s12664-021-01230-3.
   PubMed Web of Science ®Google Scholar
• Lisman T, Porte RJ. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood. 2010;16(6):878–885. doi: 10.1182/blood-2010-02-261891.
   Web of Science ®Google Scholar
• Kalaitzakis E, Rosengren A, Skommevik T, et al. Coronary artery disease in patients with liver cirrhosis. Dig Dis Sci. 2010;55(2):467–475. doi: 10.1007/s10620-009-0738-z.
   PubMed Web of Science ®Google Scholar
• McAvoy NC, Kochar N, McKillop G, et al. Prevalence of coronary artery calcification in patients undergoing assessment for orthotopic liver transplantation. Liver Transpl. 2008;14(12):1725–1731. doi: 10.1002/lt.21540.
   PubMed Web of Science ®Google Scholar
• Paul B, Lewinska M, Andersen JB. Lipid alterations in chronic liver disease and liver cancer. JHEP Rep. 2022;4(6):100479. doi: 10.1016/j.jhepr.2022.100479.
   PubMedGoogle Scholar
• Feng R, Guo X, Kou Y, et al. Association of lipid profile with decompensation, liver dysfunction, and mortality in patients with liver cirrhosis. Postgrad Med. 2021;133(6):626–638. doi: 10.1080/00325481.2021.1930560.
   PubMed Web of Science ®Google Scholar